An update on emerging drugs in osteosarcoma: towards tailored therapies?. (3rd July 2019)
- Record Type:
- Journal Article
- Title:
- An update on emerging drugs in osteosarcoma: towards tailored therapies?. (3rd July 2019)
- Main Title:
- An update on emerging drugs in osteosarcoma: towards tailored therapies?
- Authors:
- Hattinger, Claudia Maria
Patrizio, Maria Pia
Magagnoli, Federica
Luppi, Silvia
Serra, Massimo - Abstract:
- ABSTRACT: Introduction : Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operative chemotherapy with drugs that have been used since decades. Areas covered : This review is intended to summarize the new agents and therapeutic strategies that are under clinical evaluation in HGOS, with the aim to increase the cure probability of this highly malignant bone tumor, which has not significantly improved during the last 30–40 years. The list of drugs, compounds and treatment modalities presented and discussed here has been generated by considering only those that are included in presently ongoing and recruiting clinical trials, or which have been completed in the last 2 years with reported results, on the basis of the information obtained from different and continuously updated databases. Expert opinion : Despite HGOS is a rare tumor, several clinical trials are presently evaluating different treatment strategies, which may hopefully positively impact on the outcome of patients who experience unfavorable prognosis when treated with conventional therapies. Trial registration: ClinicalTrials.gov identifier: NCT01459484. Trial registration: ClinicalTrials.gov identifier: NCT01669369. Trial registration: ClinicalTrials.gov identifier: NCT00134030. Trial registration: ClinicalTrials.gov identifier:ABSTRACT: Introduction : Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operative chemotherapy with drugs that have been used since decades. Areas covered : This review is intended to summarize the new agents and therapeutic strategies that are under clinical evaluation in HGOS, with the aim to increase the cure probability of this highly malignant bone tumor, which has not significantly improved during the last 30–40 years. The list of drugs, compounds and treatment modalities presented and discussed here has been generated by considering only those that are included in presently ongoing and recruiting clinical trials, or which have been completed in the last 2 years with reported results, on the basis of the information obtained from different and continuously updated databases. Expert opinion : Despite HGOS is a rare tumor, several clinical trials are presently evaluating different treatment strategies, which may hopefully positively impact on the outcome of patients who experience unfavorable prognosis when treated with conventional therapies. Trial registration: ClinicalTrials.gov identifier: NCT01459484. Trial registration: ClinicalTrials.gov identifier: NCT01669369. Trial registration: ClinicalTrials.gov identifier: NCT00134030. Trial registration: ClinicalTrials.gov identifier: NCT00180908. Trial registration: ClinicalTrials.gov identifier: NCT00470223. Trial registration: ClinicalTrials.gov identifier: NCT01532687. Trial registration: ClinicalTrials.gov identifier: NCT02357810. Trial registration: ClinicalTrials.gov identifier: NCT03163381. Trial registration: ClinicalTrials.gov identifier: NCT02432274. Trial registration: ClinicalTrials.gov identifier: NCT02048371. Trial registration: ClinicalTrials.gov identifier: NCT02389244. Trial registration: ClinicalTrials.gov identifier: NCT02243605. Trial registration: ClinicalTrials.gov identifier: NCT02867592. Trial registration: ClinicalTrials.gov identifier: NCT03210714. Trial registration: ClinicalTrials.gov identifier: NCT03526250. Trial registration: ClinicalTrials.gov identifier: NCT03213678. Trial registration: ClinicalTrials.gov identifier: NCT03718091. Trial registration: ClinicalTrials.gov identifier: NCT03233204. Trial registration: ClinicalTrials.gov identifier: NCT03698994. Trial registration: ClinicalTrials.gov identifier: NCT03220035. Trial registration: ClinicalTrials.gov identifier: NCT03220035. Trial registration: ClinicalTrials.gov identifier: NCT02689336. Trial registration: ClinicalTrials.gov identifier: NCT03678883. Trial registration: ClinicalTrials.gov identifier: NCT01962103. Trial registration: ClinicalTrials.gov identifier: NCT02945800. Trial registration: ClinicalTrials.gov identifier: NCT01669369. Trial registration: ClinicalTrials.gov identifier: NCT03598595. Trial registration: ClinicalTrials.gov identifier: NCT02644460. Trial registration: ClinicalTrials.gov identifier: NCT02517918. Trial registration: ClinicalTrials.gov identifier: NCT03002805. Trial registration: ClinicalTrials.gov identifier: NCT02013336. Trial registration: ClinicalTrials.gov identifier: NCT02536183. Trial registration: ClinicalTrials.gov identifier: NCT02557854. Trial registration: ClinicalTrials.gov identifier: NCT02390843. Trial registration: ClinicalTrials.gov identifier: NCT03643133. Trial registration: ClinicalTrials.gov identifier: NCT03006848. Trial registration: ClinicalTrials.gov identifier: NCT03676985. Trial registration: ClinicalTrials.gov identifier: NCT03277924. Trial registration: ClinicalTrials.gov identifier: NCT03190174. Trial registration: ClinicalTrials.gov identifier: NCT02304458. Trial registration: ClinicalTrials.gov identifier: NCT02406781. Trial registration: ClinicalTrials.gov identifier: NCT02502786. Trial registration: ClinicalTrials.gov identifier: NCT03860207. Trial registration: ClinicalTrials.gov identifier: NCT03320330. Trial registration: ClinicalTrials.gov identifier: NCT03610490. Trial registration: ClinicalTrials.gov identifier: NCT02100891. Trial registration: ClinicalTrials.gov identifier: NCT02508038. Trial registration: ClinicalTrials.gov identifier: NCT03356782. Trial registration: ClinicalTrials.gov identifier: NCT01953900. Trial registration: ClinicalTrials.gov identifier: NCT03618381. Trial registration: ClinicalTrials.gov identifier: NCT03462316. Trial registration: ClinicalTrials.gov identifier: NCT02487979. … (more)
- Is Part Of:
- Expert opinion on emerging drugs. Volume 24:Number 3(2019)
- Journal:
- Expert opinion on emerging drugs
- Issue:
- Volume 24:Number 3(2019)
- Issue Display:
- Volume 24, Issue 3 (2019)
- Year:
- 2019
- Volume:
- 24
- Issue:
- 3
- Issue Sort Value:
- 2019-0024-0003-0000
- Page Start:
- 153
- Page End:
- 171
- Publication Date:
- 2019-07-03
- Subjects:
- Osteosarcoma -- chemotherapy -- drug resistance -- pharmacogenomics -- biomarkers -- targeted drugs -- tailored therapy
Drugs -- Research -- Handbooks, manuals, etc
Drugs -- Design -- Periodicals
615.1072 - Journal URLs:
- http://informahealthcare.com/journal/emd ↗
http://informahealthcare.com ↗
http://iris.ashley-pub.com/vl=930529/cl=16/nw=1/rpsv/journal/journal4_home.htm ↗ - DOI:
- 10.1080/14728214.2019.1654455 ↗
- Languages:
- English
- ISSNs:
- 1472-8214
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002950
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17274.xml